Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD
How to cite: Gomez-Mancilla, B.; Erickson, C.; Pedapati, E.V.; Painbeni, E.; Bonfils, G.; Schmitt, L.M.; Sachs, H.; Will, M.; Destefano, L.; Westerkamp, G.; De Souza, A.; Pohl, O.; Laufer, O.; Issachar, G.; Hyvelin, J.; Durham, L.A. Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Preprints 2024, 2024031581. https://doi.org/10.20944/preprints202403.1581.v1 Gomez-Mancilla, B.; Erickson, C.; Pedapati, E.V.; Painbeni, E.; Bonfils, G.; Schmitt, L.M.; Sachs, H.; Will, M.; Destefano, L.; Westerkamp, G.; De Souza, A.; Pohl, O.; Laufer, O.; Issachar, G.; Hyvelin, J.; Durham, L.A. Safety, Tolerability and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist), in a Randomized Clinical Trial in a Subgroup of Patients with ASD. Preprints 2024, 2024031581. https://doi.org/10.20944/preprints202403.1581.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)